Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo

This article was originally published in The Pink Sheet Daily

Executive Summary

The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”

You may also be interested in...



Bristol/Gilead HIV Combo Will Go To FDA In Mid-2006

The combination of Bristol’s Sustiva and Gilead’s Truvada would be the first complete HAART regimen available as a single once-daily tablet.

Bristol/Gilead HIV Combo Will Go To FDA In Mid-2006

The combination of Bristol’s Sustiva and Gilead’s Truvada would be the first complete HAART regimen available as a single once-daily tablet.

Bristol/Gilead Triple Combination HIV Therapy Has Back-Up

Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture

Related Content

Topics

UsernamePublicRestriction

Register

PS058434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel